About Us

Pushing the boundaries of RNAi, CRISPR, and testing technologies
Mirimus was established in 2010 with the goal of creating a scalable and cost effective pipeline for model generation by harnessing the power of RNAi and CRISPR technologies to develop animal models which are crucial for preclinical evaluation of new therapeutics. Through cutting edge technology, powerful predictive tools, and vital partnerships, Mirimus is paving the path to develop safer and more effective therapeutics by pin-pointing potential toxicities, validation, and disease modeling.

In 2020, responding to the Covid-19 pandemic, our team of experts mobilized their scientific expertise to develop a safe, regular, affordable, and non-invasive testing methodology. Our testing protocol, SalivaClear, is successful in detecting and monitoring SARS-COV-2 infection within communities around the country, allowing them to return to in-person operations. Mirimus’ goal is to facilitate the re-opening of the US economy by increasing access to testing and preventing large-scale outbreaks.

Our Team

Prem Premsrirut, MD, PhD

Founder & CEO

Veronica Andrews

Chief of Staff

David Eads

Chief Financial Officer

Sean Seibel

Chief Product & Technology Officer

Ana Vasileva, PhD

Director of Scientific Operations

Chia-Lin Wang, PhD

Director of Genetic Engineering

Yuting Yang, PhD

Director of Embryology

Gerard Garramone

Director of Operations

Hui-Ting Cheng, MS, PhD

Head Scientist

Daniel Neumann

Head of Logistics

Nadia Khan, PhD

Senior Scientist

Helen Hoxie

Lab Scientific Manager

Elmer Gabutan, MD

Senior Scientist

Stephanie Cevallos, PhD

Senior Scientist

Giuseppe Militello, PhD

Senior Scientist

Our Advisors

Stephen Chang, PhD

Strategic Advisor

James Kehler, PhD, VMD

Scientific Advisor

Our Founders

Lukas Dow, PhD


Johannes Zuber, PhD, MD


Scott W. Lowe, PhD

Founder, Strategic Advisor

Christof Fellman, PhD


Stephen Elledge, PhD


Greg Hannon, PhD